Study Examining PrEP-001 in Healthy Subjects

NCT03220048 ↗

Phase 2 Completed 66 enrolled Hvivo Prep Biopharm Limited · collab

RandomizedParallel-groupDouble-blindPrevention

Summary

Phase 2 study, looking at the prophylactic efficacy, safety and tolerability to a repeated nasal dose of study drug after being infected with Influenza A/Perth/16/2009 (H3N2) virus.

Timeline

Start: 2015-09-16
Primary completion: 2016-02
Completion: 2016-02

Publications

Malcolm BA, Aerts CA, Dubois KJ, Geurts FJ, Marien K, Rusch S, Van Dijck AH, Verloes R, Vingerhoets J. PrEP-001 prophylactic effect against rhinovirus and influenza virus - RESULTS of 2 randomized trials. Antiviral Res. 2018 May;153:70-77. doi: 10.1016/j.antiviral.2018.03.005. Epub 2018 Mar 19.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	PrEP-001	Unknown	6400 ug	Intranasal

Indications

No indication recorded.